Relmada reports 90% ORR at any time point in Phase 2 NDV-01 trial for NMIBC

RELMADA THERAPEUTICS, INC.

90% (18/20) achieved high-grade disease-free status at any time point; 85% ORR at 3 months.
100% complete response in CIS patients (2/2); 88.8% high-grade recurrence-free survival in papillary disease.
NDV-01 well tolerated; no treatment-related AEs >Grade 1, no discontinuations due to AEs.
Study continues enrolling; 26 patients enrolled, 20 reached 3-month assessment, 7 at 6 months.
Administration time <10 minutes; data support potential bladder-sparing outpatient therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.